Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating ...
Regeneron REGN0.26%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.65%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...